**Name of journal:** World Journal of Hepatology  

**Manuscript NO:** 65720  

**Title:** Heterogeneity of nonalcoholic fatty liver disease: Implications for clinical practice and research activity with an outlook for the future  

**Reviewer’s code:** 00001787  

**Position:** Editorial Board  

**Academic degree:** MD  

**Professional title:** Adjunct Professor  

**Reviewer’s Country/Territory:** Italy  

**Author’s Country/Territory:** India  

**Manuscript submission date:** 2021-03-14  

**Reviewer chosen by:** AI Technique  

**Reviewer accepted review:** 2021-03-15 11:23  

**Reviewer performed review:** 2021-03-18 15:57  

**Review time:** 3 Days and 4 Hours  

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [ ] Anonymous</td>
<td>[Y] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>statements</td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
I read with interest this review MS focusing on a new definition of NAFLD PROCEEDING TO MAFLD which has been defined as "game changer redefining fatty liver disease for adults and children" by an innovative letter to the Editor recently published by the Journal of Hepatology. The review article is well developed, thoughtful and innovative. I have a couple of suggestions: a) one of the main purposes to change the definition of NAFLD is to address the cardiovascular risk of the disease. To this regard, I feel the Authors should summarize some of the subsection to add a focus on cardiovascular risk of MAFLD, b) MAFLD should be added to the title and emphasized in the abstract to encourage readers attention. No additional suggestions on this side.
PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 65720

Title: Heterogeneity of nonalcoholic fatty liver disease: Implications for clinical practice and research activity with an outlook for the future

Reviewer’s code: 03478404

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Associate Professor

Reviewer’s Country/Territory: Romania

Author’s Country/Territory: India

Manuscript submission date: 2021-03-14

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-14 17:47

Reviewer performed review: 2021-03-21 08:48

Review time: 6 Days and 15 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[Y] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[Y] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer statements</td>
<td>Peer-Review: [Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[Y] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

I truly appreciate all the hard work the study group invested in this review. The concept and design are original and very well-conceived and organized. Everything is analyzed in detail (including epigenetic factors) and all paragraphs contain the most informative data. The figures are of high quality and very useful for practice (especially the 4th one). Tables are accurate and the 2nd one includes all the ongoing therapies regarding NAFLD (the liver aspect) with detail on targets and mechanisms of action. It is true that the manuscript is a bit long, but it would be a pity to delete any sentence. The manuscript well deserves to be published. Minor correction: Background: Page 6 - When the authors wrote “For the same reasons, Polyzos and Mantzoros…” – reference is missing from the References list. Please add: “Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism. 2020 Oct;111S:154318. doi: 10.1016/j.metabol.2020.154318.” Other comments: 1. There are no « Conflict-of-Interest Disclosure Form » and « Copyright License Agreement ». Please add. Please write the manuscript according to the Journal style. References are up-to-date, but missing PMID and DOI, as well as other requirements of the Journal style. Please add. 2. Minor English language revision is required (i.e – “The prevalence of NAFLD and risk of nonalcoholic steatohepatitis (NASH) is decreasing order of frequency are seen…” and others).